Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report

Keisuke Uchida,Yoshinori Ozono,Naomi Uchiyama,Hiroshi Hatada,Kenichi Nakamura,Yuri Komaki,Hisayoshi Iwakiri,Satoru Hasuike,Kenji Nagata,Yuichiro Sato,Hiroshi Kawakami
DOI: https://doi.org/10.1097/md.0000000000030486
IF: 1.6
2022-09-03
Medicine
Abstract:Hepatocellular carcinoma (HCC) is the sixth most common type of cancer globally. Since 2020, combination treatment with atezolizumab and bevacizumab were approved in patients with unresectable HCC in Japan, and atezolizumab plus bevacizumab is the first-line treatment for unresectable HCC.
medicine, general & internal
What problem does this paper attempt to address?